Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Prevalence of Chronic spontaneous urticaria

18 evidence topics · 13 sources

United States: diagnosed CSU period prevalence in three US databases, 2012 to 2018, Novartis-funded

“This study aimed to estimate the age- and/or sex-standardized incidence and prevalence of diagnosed CSU in the US population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The study population consisted of adult (aged ≥ 18 years) and pediatric (aged < 18 years) patients with diagnosed CSU based on ≥ 2 relevant International Classification of Diseases version 9 and/or 10 (ICD-9 and/or ICD-10) codes recorded ≥ 6 weeks apart.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The age- and sex-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum EHR during the identification period (2012–2018) was 0.039 and 0.066 per 100 person-years, respectively, while the prevalence was 0.120% and 0.193%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in Optum CDM (2012–2018) was 0.094 and 0.109 per 100 person-years, respectively, while the prevalence was 0.277% and 0.304%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The age-standardized incidence rate of diagnosed CSU among adult and pediatric populations in MarketScan (2012–2017) was 0.102 and 0.097 per 100 person-years, respectively, while the prevalence was 0.256% and 0.264%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Our study reports the standardized period prevalence of diagnosed CSU among adults from 0.120% to 0.277% across three databases” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This research was funded by Novartis Pharma AG, Basel, Switzerland.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

United States: annual prevalence trend of diagnosed CSU, 2012 to 2018, Novartis-funded study
United States: 12-month prevalence of self-reported physician-diagnosed CSU of 0.78% in adults, 2019 National Health and Wellness Survey, Novartis-funded